We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DLX:NYSEDeluxe Corporation Analysis

Data as of 2026-03-29 - not real-time

$26.99

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Deluxe trades at $26.99, just below its 20‑day SMA (27.26) but above the 50‑day SMA (26.69) and well above the 200‑day SMA (20.97), indicating a short‑term pullback within a longer‑term bullish framework. The RSI sits at 49.9, essentially neutral, while the MACD histogram is slightly negative and the signal line is flagged “bearish,” suggesting modest downside pressure in the next few days. Volume is increasing, and the technical support at $25.65 provides a cushion before the next resistance at $28.31. The stock’s beta (~0.94) points to lower market‑risk volatility, yet the 30‑day volatility of ~29.5% is relatively high, reflecting price swings.
From a valuation standpoint, DLX appears undervalued – its trailing PE of 15 is well below the industry average of 28, and the DCF‑derived fair value of $29.67 implies roughly a 21% upside. The forward PE of 6.3 signals strong earnings growth expectations, while a 4.45% dividend yield and a 66% payout ratio are backed by positive free cash flow ($188 M) that comfortably exceeds the annual dividend outlay. However, the balance sheet is levered, with a debt‑to‑equity ratio over 220 and total debt of $1.5 B versus cash of $37 M, raising concerns about financial flexibility. Overall, the combination of attractive yield, solid cash generation, and a sizable valuation gap supports a buy stance for investors comfortable with moderate leverage risk.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • price near technical support at $25.65
  • neutral RSI and modest bearish MACD signal
  • high dividend yield of 4.45%

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF upside of ~21% to $29.67
  • forward PE of 6.3 indicating earnings acceleration
  • stable free cash flow covering dividend

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • elevated debt‑to‑equity ratio over 220
  • consistent dividend income
  • long‑term cash flow generation

Key Metrics & Analysis

Financial Health

Revenue Growth2.80%
Profit Margin3.85%
P/E Ratio15.0
ROE12.63%
ROA5.69%
Debt/Equity221.65
P/B Ratio1.8
Op. Cash Flow$270.6M
Free Cash Flow$188.4M
Industry P/E28.1

Technical Analysis

TrendBullish
RSI49.9
Support$25.65
Resistance$28.31
MA 20$27.26
MA 50$26.69
MA 200$20.97
MACDBearish
VolumeIncreasing
Fear & Greed Index65.98

Valuation

Fair Value$29.67
Target Price$32.67
Upside/Downside21.03%
GradeUndervalued
TypeBlend
Dividend Yield4.45%

Risk Assessment

Beta0.94
Volatility29.53%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.